Six months of hybrid closed loop in the real‐world: An evaluation of children and young adults using the 670G system
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe glycemic and psychosocial outcomes in youth with type 1 diabetes using a hybrid closed loop (HCL) system. SUBJECTS: Youth with type 1 diabetes (2-25 years) starting the 670G HCL system for their diabetes care were enrolled in an observational study. METHODS: Prospective data collection occurred during routine clinical care and included glycemic variables (sensor time in range [70-180 mg/dL], HbA1c), and psychosocial variables (Hypoglycemia Fear Survey [HFS]; Problem Areas in Diabetes [PAID]). Mixed models were used to analyze change across time. RESULTS: Ninety-two youth (mean age 15.7 ± 3.6 years, 50% female, HbA1c 8.8% ± 1.8%) started HCL for their diabetes care. Youth used Auto Mode 65.5% ± 3.0% of the time at month 1, which decreased to 51.2% ± 3.4% at month 6 (P = .001). Sensor time in range increased from 50.7% ± 1.8% at baseline to 56.9% ± 2.1% at 6 months (P = .007). HbA1c decreased from 8.7% ± 0.2% at baseline to 8.4% ± 0.2% after 6 months of use (P ≤ .0001), with the greatest HbA1c decline in participants with high baseline HbA1c. Increased percent time in auto mode was associated with lower HbA1c (P = .02). Thirty percent of youth discontinued HCL in the first 6 months of use. There were no changes in the HFS or PAID scores across time. CONCLUSIONS: HCL use is associated with improved glycemic control and no change in psychosocial outcomes in this clinical sample. The decline in HCL use across time suggests that youth experience barriers in sustaining use of HCL. Further research is needed to understand reasons for HCL discontinuation and determine intervention strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“The mean sensor glucose was recorded and sensor glucose values were classified as percent time < 55, <70, 70-180, >180, and >250 mg/ dL.(19) Glycemic metrics were analyzed for all participants using Auto Mode at each visit (defined as >10% Auto Mode use).”
MethodAssessment of Diabetes-Related Distress
Polonsky, W. H., Anderson, B. J., Lohrer, P. A., Welch, G., Jacobson, A. M., Aponte, J. E., & Schwartz, C. E. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.754 · Cited by 1,497
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 1×
“This improvement in HbA1c is particularly remarkable as 37% of participants were 14-17 years of age, the age range when HbA1c tends to be the highest.(3,7) Notably, the participants with the highest baseline HbA1c experienced the greatest decline in HbA1c after 6 months of Auto Mode use.”
BackgroundSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Polonsky, W. H., Hessler, D., Ruedy, K. J., & Beck, R. W. (2017) · Diabetes Care · doi:10.2337/dc17-0133 · Cited by 346 · cited 1×
“Only the Worry subscale was used for this study as this metric has been used in the past for other diabetes technology studies.(22) In addition the worry subscale has demonstrated acceptable factor structure in pediatrics whereas the behavior subscale has been called into question.”
MethodPsychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes
Gonder-Frederick, L. A., Schmidt, K. M., Vajda, K. A., Greear, M. L., Singh, H., Shepard, J. A., & Cox, D. J. (2011) · Diabetes Care · doi:10.2337/dc10-1343 · Cited by 337 · cited 1×
“The HFS is a self-reported questionnaire of behavior and worry related to hypoglycemia and its negative consequences.(20,21) Only the Worry subscale was used for this study as this metric has been used in the past for other diabetes technology studies.”
MethodOne year clinical experience of the first commercial hybrid closed-loop system
Lal, R. A., Basina, M., Maahs, D. M., Hood, K., Buckingham, B., & Wilson, D. M. (2019) · Diabetes Care · doi:10.2337/dc19-0855 · Cited by 215
Barnard, K. D., Wysocki, T., Allen, J. M., Elleri, D., Thabit, H., Leelarathna, L., Gulati, A., Nodale, M., Dunger, D. B., Tinati, T., et al. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000025 · Cited by 159
Markowitz, J. T., Volkening, L. K., Butler, D. A., Antisdel‐Lomaglio, J., Anderson, B. J., & Laffel, L. M. B. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03434.x · Cited by 122
A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm
Messer, L. H., Berget, C., & Forlenza, G. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0105 · Cited by 100
Self-citationCooper, M. N., Lin, A., Alvares, G. A., de Klerk, N. H., Jones, T. W., & Davis, E. A. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12469 · Cited by 75 · cited 1×
“Challenges with glycemic control and self-management in this difficult developmental period also negatively impact psychological well-being, leading to a mutual deterioration of glycemic control and quality of life in this vulnerable population.(5,6) Received: 2 October 2019 Revised: 18 November 2019 Accepted: 5 Decem…”
BackgroundPsychosocial impact of the bionic pancreas during summer camp
Weissberg-Benchell, J., Hessler, D., Polonsky, W. H., & Fisher, L. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816640289 · Cited by 47
Cited by
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Self-citationPhillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationBergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Collyns, O. J., Meier, R. A., Betts, Z. L., Chan, D. S. H., Frampton, C., Frewen, C. M., Hewapathirana, N. M., Jones, S. D., Roy, A., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2250 · Cited by 276
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Metadata
- Authors
- Berget, C., Messer, L. H., Vigers, T., Frohnert, B. I., Pyle, L., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P.
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2020-01-07
- Volume
- 21
- Issue
- 2
- Pages
- 310-318
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W2995085977
- Cited by
- 138
- References
- 15
- FWCI
- 13.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.